triumph-1 retatrutide Alexandra Sowa, MD | 🚨TRIUMPH-1 data is here‼️ ~28% weight loss. Nearly half lost ≥30% We are entering an entirely new era of obesity medicine 💉🩺 A Study of Retatrutide (LY3437943)

Frequently Asked Questions About TB-500 Nasal Spray What is TB-500 and how does it differ from Thymosin Beta-4

CagriSema's Advantages: First to Market: 6-12 month head start Leverages Wegovy Success: Built-in brand recognition Proven Semaglutide Component: Half the drug is already approved Strong Diabetes Data: Positions for dual indication No Dysesthesia: Cleaner safety profile in one key area Retatrutide's Advantages: Higher Efficacy: 28.7% vs 20.4% (8.3 points more) Superior BP Reduction: -14 mmHg vs likely similar to semaglutide Single Molecule: Potentially easier manufacturing Multiple Indications: OA, OSA, obesity, diabetes trials Novel Class: First triple agonist = strong IP protection The Verdict: Market Will Support Both These medications won't compete head-to-head

Tirzepatide nausea affects 25% of users but typically resolves by week 12

The medication itself arrived quickly within the two-day shipping wind, but I could have done without the maladroit notification experience

Create a Provider Account Collapsible content Research Partners As a research partner, your goal is to ensure accuracy and reproducibility